Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 9

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 9
---

assets and there are no active research and development programs based on our drug delivery technologies.

| 4 |

Our Strategy

In early 2023, we decided
to re-position the Company as therapeutics (as opposed to drug delivery) company and we began looking for additional assets to complement
our MTX110 programs. The delivery of proof-of-concept clinical data is the primary focus of our business model going forward.

Our proprietary drug delivery
technologies are no longer a key priority for the Company.

Development

Our intention is to build
a balanced portfolio of clinical-stage development assets, ideally with a focus on rare / orphan indications. eRapa was in-licensed in
April 2024 and is being developed for FAP and NMIBC. We expect to begin enrolling a multi-center registrational Phase 3 trial in FAP in
the first half of 2025. The Phase 2 trial in NMIBC is ongoing. Tolimidone, which was in-licensed in December 2023, is a Phase 2 ready
asset which we intend to develop for T1D. MTX110 is currently in Phase 1 development for three rare / orphan brain cancers.

Our aim is to develop our
clinical assets to proof-of-concept stage before securing partners to undertake the most expensive, later stage development.

Our research and development programs may,
like MTX110, be based on one or more of our enabling technologies.

Manufacturing

We do not intend to establish
our own manufacturing capabilities. For clinical trial material we utilize GMP-certified contract manufacturers.

Commercialization

Once proof-of-concept has
been established, we intend to seek to license our products to a partner who would complete the development, and subsequently market and
sale, of the product in an agreed upon licensed territory. In addition to reimbursement of development costs, the partner would be expected
to make milestone payments based on sales targets and royalty payments.

| 5 |

Pipeline and Platform Technologies

We
are actively pursuing the development of eRapa in FAP, tolimidone in T1D and MTX110 in three indications. Our development pipeline is
as follows:

Our Corporate Information

Our principal executive offices are located at 1 Caspian Point, Caspian
Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our principal executive office is +44 29 20480 180. Our corporate website
is located at www.biodexapharma